Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Bollywood Celebrity Abhishek Bachchan Named Ambassador for END7 Campaign

Published: Friday, February 14, 2014
Last Updated: Friday, February 14, 2014
Bookmark and Share
Spotlight on neglected tropical diseases could drive India’s next big public health success.

The Global Network for Neglected Tropical Diseases (Global Network) has named Abhishek Bachchan, Bollywood superstar and international humanitarian, as its first official END7 campaign ambassador in India to help raise awareness of neglected tropical diseases (NTDs).

Mr. Bachchan joins the END7 campaign at a crucial time, with India at the tipping point of achieving control and elimination of five NTDs affecting 500 million people by 2020.

“India represents 35 percent of the total global burden for NTDs, causing massive suffering among our poorest citizens. As a parent, I am deeply moved by the devastating toll of NTDs on children, and I want to ensure that no Indian child has to suffer needlessly,” said Mr. Bachchan. “I am proud to serve as the END7 campaign’s ambassador in India and hope that others will join me in ridding our country of these preventable diseases.”

Maintaining the progress that India has gained against NTDs is vital right now. Abhishek Bachchan will play a key role in drawing attention to NTDs as an achievable health priority for India, educating the public about the impact of NTDs and the importance of complying with free NTD treatment programs, while also encouraging national and state level policymakers to continue making the cost-effective investment in NTD programs.

“We have already defeated smallpox, guinea worm and polio in India. NTDs can be our next major public health success story, and we are on track to eliminate lymphatic filariasis very soon. A focus on NTD control and elimination also represents one of the best investments we can make in the health and economic future of our country,” said Anshu Prakash, Joint Secretary of the Ministry of Health and Family Welfare. “We are happy that the Global Network is supporting our efforts to control and eliminate these diseases of poverty.”

“India currently runs some of the largest NTD control and elimination programs in the world, signaling its commitment to improving the plight of millions of people,” said Dr. Neeraj Mistry, managing director of the Global Network. “By continuing to prioritize NTDs and building up the ability to deliver treatments, India can be a global leader in efforts to defeat NTDs once and for all.”

It costs approximately 50 cents (31 rupees) to treat and protect one person for an entire year against all seven of the most common NTDs. Pills to treat NTDs are donated by pharmaceutical companies and many programs use existing infrastructure, such as schools and community centers, to administer the treatments, making NTD treatment one of most cost-effective public health initiatives available.

The seven most common NTDs-hookworm, ascariasis (roundworm), trichuriasis (whipworm), schistosomiasis (snail fever), lymphatic filariasis (elephantiasis), onchocerciasis (river blindness) and trachoma-infect more than 1 in 6 people worldwide. They cause blindness, massive swelling in appendages and limbs, disfigurement, severe malnutrition and anemia. NTDs prevent children from growing and learning. They reduce adults’ economic productivity and ability to care for their families, keeping communities trapped in a cycle of poverty and disease.

END7 is the first and only global public awareness campaign dedicated to controlling and eliminating the seven most common NTDs by 2020. It was launched in 2012 by the Global Network for Neglected Tropical Diseases, an advocacy initiative of the Sabin Vaccine Institute.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Charting Kidney Cancer Metabolism
Changes in cell metabolism are increasingly recognized as an important way tumors develop and progress, yet these changes are hard to measure and interpret. A new tool designed by MSK scientists allows users to identify metabolic changes in kidney cancer tumors that may one day be targets for therapy.
Insights into the Function of the Main Class of Drug Targets
About thirty percent of all medical drugs such as beta-blockers or antidepressants interact with certain types of cell surface proteins called G protein coupled receptors.
Visualizing a Cancer Drug Target at Atomic Resolution
Using cryo-electron microscopy, researchers were able to view, in atomic detail, the binding of a potential small molecule drug to a key protein in cancer cells.
Honey’s Potential to Save Lives
The healing powers of honey have been known for thousands of years.
3-D Printed Lifelike Liver Tissue for Drug Screening
A team led by engineers at the University of California, San Diego has 3D-printed a tissue that closely mimics the human liver's sophisticated structure and function. The new model could be used for patient-specific drug screening and disease modeling.
Cytoskeleton Crew
Findings confirm sugar's role in helping cancers survive by changing cellular architecture.
Biomarker for Recurring HPV-Linked Oropharyngeal Cancers
A look-back analysis of HPV infection antibodies in patients treated for oropharyngeal (mouth and throat) cancers linked to HPV infection suggests at least one of the antibodies could be useful in identifying those at risk for a recurrence of the cancer, say scientists at the Johns Hopkins University.
Valvena, GSK Sign New R&D Collaboration
Valneva to supply process development services for EB66® -based Influenza vaccines.
Light Signals from Living Cells
Fluorescent protein markers delivered under high pressure.
Cellular 'Relief Valve'
A team led by scientists at The Scripps Research Institute (TSRI) has solved a long-standing mystery in cell biology by showing essentially how a key “relief-valve” in cells does its job.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!